Anti-Protein Kinase C monoclonal antibody, clone ND6

Purpose Objective: The aim of this study was to explore the ability of Kang-shu Jian-gu granules to enhance bone density in a rat model of osteoporosis, to determine the molecular mechanisms of the anti-osteoporotic effects of Protein Kinase C (PKC) in vivo. and to provide reference information for the clinical treatment of osteoporosis. Methods: A rat model of osteoporosis was established and treated with Kang-shu Jian-gu (KSJG) granules (1.428 g/ kg). Bone mineral density (BMD), serum calcitonin (CT), osteocalcin (BGP), serum calcitonin (CT), osteocalcin (BGP), and bone calcium values were monitored. Protein expression of PRKCA and PRKCB of kidneys and bones was evaluated by Western blotting. Biological functions, signaling pathways, and key proteins involved with PRKCA and PRKCB proteins in reversing osteoporosis were identified using the STRING database. Results: Treatment with KSJG granules significantly increased levels of CT, BGP, BMD, bone calcium, and bone-specific alkaline phosphatase (BALP) (P < 0.05). Compared with the sham-surgery group (controls), expression of PRKCA and PRKCB proteins was significantly lower than that in the ovariectomy group (OVX) (P < 0.05). Relative expression levels of PRKCA and PRKCB, in kidneys and bones, were positively correlated with bone calcium levels (r(2) = 0.7762, r(2) = 0.6033, respectively), but negatively correlated with BALP (r(2) = 0.8746, r(2) = 0.8166, respectively) (P < 0.05). There was direct interaction of PRKCA with PLD1, ARHGDIA, PLD2, RHOA, RAC1, MAP2K1, BRAF, PLCB1, and PICK1. PRKCB interacted directly with PIK3CG, RPS6KB1, and MTOR. PRKCA and PRKCB were involved principally in estrogen receptor signaling pathways. Conclusion: Kang shu Jian gu granules can enhance bone mineral density in a rat model of osteoporosis. Protein expression of PRKCA and PRKCB can be regulated by Kang shu Jian gu granules, which mediate bone cell differentiation and enhance bone density.

This group has previously reported the mapping of a novel locus for autosomal dominant retinitis pigmentosa (adRP) in a South African kindred to 17q. Using a new series of microsatellite markers in this study, two-point and multipoint analysis provide evidence for the localization of the disease gene to the 17q22 region. In addition, a second South African adRP family is shown to be linked to this 17q22 locus. Disease-associated haplotypes constructed for both families and multipoint linkage analysis place the gene in the 10-cM interval between D17S1607 and D17S1874. Three candidate genes on 17q were investigated: PDEG, the gamma subunit of rod phosphodiesterase; TIMP2, tissue inhibitor of metalloproteinases-2; and PRKCA, protein kinase C alpha. Recombination events between the adRP locus and: (1) a single-stranded conformation polymorphism in PDEG; and (2) a restriction fragment length polymorphism in TIMP2 provided evidence for the exclusion of these candidate genes as being responsible for adRP in the South African kindred.